上海醫藥集團股份有限公司
Shanghai Pharmaceuticals Holding Co., Ltd.*
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 02607)

FURTHER INFORMATION IN RELATION TO THE ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2024

Reference is made to the annual report for the year ended 31 December 2024 (the "**Annual Report**") of Shanghai Pharmaceuticals Holding Co., Ltd. (the "**Company**") published on 25 April 2025. Unless otherwise specified, capitalised terms used herein shall have the same meanings as those defined in the Annual Report.

The announcement is to provide further information about the connected transactions and the Share Option Scheme of the Company.

CONNECTED TRANSACTIONS

Reference is made to the section headed "SIGNIFICANT RELATED PARTIES" on page 66 and the section headed "5. Related party transaction" in Note 7 to the Financial Statements on page 248 of the Annual Report (the "**Note**"), the Company would like to clarify the information in the Annual Report as follows:

(i) transactions relating to the purchase of goods from and the sales of goods to Yunnan Baiyao Group Co., Ltd. and its subsidiaries as disclosed in the Note, refer to the continuing connected transactions under the sales and procurement framework agreement entered into between the Company and Yunnan Baiyao Group Co., Ltd., details of which have been set out on page 63 of the Annual Report;

(ii) transactions relating to the purchase of goods from Wing Fat Printing Limited and its subsidiaries as disclosed in the Note, refer to the continuing connected transactions under the procurement framework agreement entered into between the Company and Wing Fat Printing Limited, details of which have been set out on page 62 of the Annual Report; and

(iii) transactions relating to the property leasing from Shanghai Pharma Group, Shanghai Yingdalai Property Co., Ltd. and Shanghai Indu-Land Property Co., Ltd. as disclosed in the Note, refer to the continuing connected transactions under the property leasing framework agreement entered into between the Company and Shanghai Pharmaceutical Group, details of which have been set out on page 60 of the Annual Report.

The Company has complied with the applicable requirements of Chapter 14A of the Hong Kong Listing Rules in respect of the continuing connected transactions mentioned in the Note above, details of which have been set out on pages 60 to 63 of the Annual Report. Save as disclosed above, none of the other related party transactions mentioned in the Note constitute connected transactions under Chapter 14A of the Hong Kong Listing Rules.

SHARE OPTION SCHEME

Reference is made to the section headed "Share Option Scheme" in the Report of the Board of Directors on page 47 of the Annual Report, the Company hereby further clarifies that as of the beginning and end of the Reporting Period, there were no options available for grant under the Company's Option Incentive Scheme. The total number of A Shares available for issue under the Option Incentive Scheme is 680,000, representing approximately 0.02% of the total number of Shares of the Company in issue as of the date of the Annual Report. The remaining life of the scheme is until the later of (i) the date on which the reserved share options have been fully exercised, which will be no later than 7 February 2026, being the closing date for the third exercise period of the reserved share options as disclosed in the Annual Report, or (ii) the date on which the reserved share options have been cancelled, if such reserved share options have not been fully exercised on or before 7 February 2026.

This announcement does not affect any other information contained in the Annual Report, and save as disclosed herein above, all other information in the Annual Report remains unchanged.

By order of the Board
Shanghai Pharmaceuticals Holding Co., Ltd.*
YANG Qiuhua
Chairman

Shanghai, the PRC, 26 September 2025

As of the date of this announcement, the executive Directors of the Company are Mr. YANG Qiuhua, Mr. SHEN Bo, Mr. LI Yongzhong and Mr. DONG Ming; the non-executive Director is Mr. ZHANG Wenxue; and the independent non-executive Directors are Mr. GU Zhaoyang, Mr. Manson FOK, Mr. WANG Zhong and Ms. MAN Kwan.

***** *For identification purposes only*